- Home
- AZN vs NVS Comparison
AZN vs NVS Comparison
Compare AZN & NVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AZN
- NVS
- Stock Information
- Founded
- AZN 1992
- NVS 1895
- Country
- AZN United Kingdom
- NVS Switzerland
- Employees
- AZN N/A
- NVS N/A
- Industry
- AZN Biotechnology: Pharmaceutical Preparations
- NVS Biotechnology: Pharmaceutical Preparations
- Sector
- AZN Health Care
- NVS Health Care
- Exchange
- AZN Nasdaq
- NVS Nasdaq
- Market Cap
- AZN 234.5B
- NVS 230.5B
- IPO Year
- AZN 1993
- NVS 1991
- Fundamental
- Price
- AZN $65.63
- NVS $104.29
- Analyst Decision
- AZN Buy
- NVS Hold
- Analyst Count
- AZN 10
- NVS 6
- Target Price
- AZN $88.80
- NVS $121.25
- AVG Volume (30 Days)
- AZN 8.6M
- NVS 1.4M
- Earning Date
- AZN 11-12-2024
- NVS 10-29-2024
- Dividend Yield
- AZN 2.26%
- NVS 3.63%
- EPS Growth
- AZN 9.79
- NVS 130.53
- EPS
- AZN 4.15
- NVS 8.58
- Revenue
- AZN $51,206,000,000.00
- NVS $49,940,000,000.00
- Revenue This Year
- AZN $17.69
- NVS $10.04
- Revenue Next Year
- AZN $7.95
- NVS $4.55
- P/E Ratio
- AZN $31.28
- NVS $11.74
- Revenue Growth
- AZN 13.81
- NVS 8.92
- 52 Week Low
- AZN $60.47
- NVS $92.35
- 52 Week High
- AZN $87.68
- NVS $120.92
- Technical
- Relative Strength Index (RSI)
- AZN 37.08
- NVS 32.83
- Support Level
- AZN $62.88
- NVS $102.40
- Resistance Level
- AZN $64.13
- NVS $103.42
- Average True Range (ATR)
- AZN 1.19
- NVS 0.92
- MACD
- AZN 0.24
- NVS -0.00
- Stochastic Oscillator
- AZN 60.00
- NVS 26.81
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
About NVS Novartis AG
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.